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Comparison of size distribution and
(Pro249-Ser258) epitope exposure in
in vitro and in vivo derived Tau fibrils
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Rosa Crespo-Rodriguez3,4, Jan R. T. van Weering5, Debby Van Dam 6,7, Peter P. De Deyn6,7,8,9, Adrian Apetri3,
Liliane Schoofs2 and Marc H. Mercken1
Abstract
Background: Although several studies demonstrate prion-like properties of Tau fibrils, the effect of size in the
seeding capacity of these aggregates is not fully understood. The aim of this study is to characterize Tau seeds by
their size and seeding capacity.
Methods: Tau aggregates were isolated from postmortem AD brain tissue and separated from low molecular
weight species by sucrose gradient ultracentrifugation. Biochemical characterization of the different fractions was
done by non-reducing Western blotting and aggregate-specific immuno-assays using in house developed anti-Tau
monoclonal antibodies, including PT76 which binds to an epitope close to the microtubule-binding domain and,
hence, also to K18. Seeding efficiency was then assessed in HEK293 cells expressing K18 FRET sensors.
Results: We observed that upon sonication of Tau aggregates different size-distributed tau aggregates are
obtained. In biochemical assays, these forms show higher signals than the non-sonicated material in some
aggregation-specific Tau assays. This could be explained by an increased epitope exposure of the smaller
aggregates created by the sonication. By analyzing human brain derived and recombinant (K18) Tau aggregates in
a cellular FRET assay, it was observed that, in the absence of transfection reagent, sonicated aggregates showed
higher aggregation induction. Preparations also showed altered profiles on native PAGE upon sonication and we
could further separate different aggregate species based on their molecular weight via sucrose gradients.
Conclusions: This study further elucidates the molecular properties regarding relative aggregate size and seeding
efficiency of sonicated vs. non-sonicated high molecular weight Tau species. This information will provide a better
knowledge on how sonication, a commonly used technique in the field of study of Tau aggregation, impacts the
aggregates. In addition, the description of PT76-based aggregation specific assay is a valuable tool to quantify K18
and human AD Tau fibrils.
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Background
Despite the large heterogeneity in neurodegenerative
diseases, protein misfolding and aggregation seems to be
a common underlying mechanism [1]. Alzheimer’s dis-
ease (AD) is characterized by amyloidβ (Aβ) formed pla-
ques and Tau deposits, called neurofibrillary tangles,
which are the main pathological hallmarks of this dis-
ease. The presence of Tau inclusions is observed in a
number of neurological diseases (Tauopathies), including
AD, frontotemporal lobar degeneration with Tau inclu-
sions, Pick’s disease, progressive supranuclear palsy, cor-
ticobasal degeneration, argyrophillic grain disease, some
prion diseases, and amyotrophic lateral sclerosis/parkin-
sonism-dementia complex [2].
Tau-mediated toxicity is believed to be exerted by
accumulation of intracellular aggregates [3] or their
intermediate products [4]. As Tau pathology has been
suggested to progress through a defined pattern over
time [5], it is plausible that an extracellular component
is contributing to the spreading of the disease [6].
Although the “Tau-spreading” hypothesis is mainly sup-
ported by indirect evidence, recent PET data have con-
firmed the progression through the different stages and
demonstrate a significant correlation between Tau path-
ology and cognitive decline [7]. While the pattern of
propagation and the brain regions affected by Tau path-
ology are identified, it is not completely understood how
this mechanism of Tau spreading occurs. In addition,
seeding experiments with Tau species derived from
interstitial fluid and cerebrospinal fluid collected from
AD individuals, suggested the presence of seeding-
competent Tau species in extracellular fluids [8].
Multiple Tau seeding experiments have shown prion-
like properties of aggregates isolated from Tau-
containing brain. The seeding efficiency of both human
AD brain and P301S mouse brain derived tau aggregates
has been already demonstrated in various cellular assays
[9]. Furthermore, injection models of Tau seeding have
been successfully developed and include injections of
P301S brain material [10], total postmortem Tauopathy
brain homogenates [11], or high molecular weight spe-
cies of Tau [12–14] in mouse brain.
There are however important differences in the struc-
ture of heparin induced recombinant Tau aggregates
[15–17], which are mostly comprised of straight fila-
ments, when comparing with AD brain-derived aggre-
gates which have a more complex paired helical filament
structure [17, 18]. There is also evidence that Tau aggre-
gates isolated from brains of patients of different Tauo-
pathies will lead to different strains when used in
seeding experiments [19–21].
In this communication, we characterized Tau seeds
from human postmortem AD brain by correlating an
intrinsic physicochemical analysis with the assessment of
functionality as competent seeds, elucidating the effects
of sonication on tau aggregates. Multiple techniques
were essential for this such as aggregation specific ana-
lysis using among others, an antibody specific for the




All in vivo experiments were conducted in strict accord-
ance with the guidelines of the Association for Assess-
ment and Accreditation of Laboratory Animal Care
International (AAALAC), with the European Communi-
ties Council Directive of 24th November 1986 (86/609/
EEC) and with protocols approved by the local Institu-
tional Animal and Use Ethical Committee. Mice express-
ing the 0N4R isoform of human Tau with a P301S
mutation were obtained from the MRC Laboratory of
Molecular Biology, Swindon (UK) and were backcrossed
on a C57bl/6 background at the JAX laboratories. Mice
were single housed in an enriched environment, indi-
vidually ventilated cages and under 12/12 h light/dark
cycles (light at 6:00 AM). At 6 months of age, mice (n =
10) were sacrificed by decapitation and spinal cord was
harvested and snap frozen.
In vitro Tau aggregation
Fibrils derived from the P301L-mutated aggregation-
prone repeat domain of 4R Tau (K18-P301L) [22] fibrils
were prepared as previously described [23]. Briefly, myc-
tagged K18-P301L Tau (Tebu Bio) (66.67 μM) was incu-
bated in the presence of 133 μM Heparin sodium salt
(MP Biomedicals) in 100mM ammonium acetate pH 7.0
at 37 °C under gentle agitation. After 5 days, samples
were centrifuged for 1 h (184,000 x g; TLA 100 rotor,
Beckman) and supernatants were kept for the analysis of
remaining monomeric K18. The pellet was washed twice
in 1mL PBS and finally resuspended in 400 μL PBS to
obtain 333.33 μMK18 fibrils, which were directly ali-
quoted and frozen (− 80 °C) or frozen after a sonication
step (Branson probe sonicator, amplitude 15%, total son-
ication time was 2 min in pulses of 2 s with 10 s interval
between them). To control for temperature effects sam-
ples were on ice during sonication.
Fibril preparation
Tau fibrils from frozen postmortem tissue from the
frontal lobe obtained from a histologically confirmed
Alzheimer patient (Braak stage VI) or from frozen spinal
cord from aged P301S Tau Tg mice [24] were partially
purified by a modified method of [25]. Briefly, frozen tis-
sue was homogenized in 10 volumes of cold buffer H
(10 mM Tris, 800 mM NaCl, 1 mM EGTA and 10%
sucrose, pH 7.4) using a glass/Teflon Potter tissue
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homogenizer at 1000 rpm (IKA Works, Inc.; Staufen,
Germany). The homogenate was subsequently centri-
fuged for 20 min at 27,000 x g. The pellet was discarded,
and the supernatant was adjusted to a final concentra-
tion of 1% (w/v) N-lauroylsarcosine and incubated with
rotation for 1.5 h at 37 °C. Subsequently, the extract was
centrifuged at 184,000 x g for 90 min at 20 °C. The pellet
was washed in PBS and resuspended in 25 times less vol-
ume of PBS, aliquoted and frozen at − 80 °C. To ensure
that seeding experiments and sucrose gradient ultracen-
trifugations are performed with samples containing
equal amounts of Tau, extracts are quantified by West-
ern blotting to estimate the total Tau content after de-
naturation (Fig. S2). In addition, the PT51/PT51
aggregate-selective MSD assay was used to compare ag-
gregated tau content [13].
Sonication was performed as described in the in vitro
Tau aggregation protocol.
Western blot
Samples (5 μL of crude paired helical filaments (PHF)
fraction or 20 μL of sucrose gradient fractions) were
diluted in NativePAGE™ Sample Buffer and Native-
PAGE™ 5% G-250 Sample Additive loaded on 3–12%
native PAGE gel (Thermo Scientific) according to the
manufacturer’s instructions. After the electrophoresis,
the gels were incubated 20min in Tris/Glycine/SDS
transfer buffer and blotted on a polyvinylidene difluoride
(PVDF) membrane. After destaining in 100% methanol
to remove excess of Coomassie dye, that was present
during the run, membranes were rinsed in Tris-buffered
saline-Tween (TBS-T) and blocked in TBS-T containing
5% non-fat dried milk. Blots were incubated with
HRPO-labelled Tau antibody (hTau10 or AT120) for 2 h
at RT or with primary antibodies followed by a second-
ary HRPO-labelled anti-mouse antibody. Detection was
done using enhanced chemiluminescence (West Dura;
Thermo Scientific) using a Amersham Imager 600 RGB
(GE Healthcare). Images were captured in automated
exposure modus.
CFP/YFP FRET cell analysis of aggregation
Tau fibril extracts, or their subfractions, were added to
Tau FRET Biosensor cells [9] as described [13]. Samples
were tested by reverse transfection (Lipofecteamine2000)
or co-incubation. After 48 h or 7 days respectively, cells
were harvested using trypsin. FRET analysis was per-
formed on a BD FACSCanto II (BD Biosciences). When
using reverse transfection, samples diluted in PBS are in-
cubated in a cell culture plate with Lipofectamine 2000.
Cells are then plated together with the Lipofectamine
Parameters analyzed were increase in FRET signal and
total number of cells.
HEK293-FRET CFP/YFP cells kindly provided by the
group of Prof. Marc Diamond [9] were maintained as an
adherent culture with cell culture medium Gibco™
DMEM supplemented with 10% Fetal Bovine Serum
(BioWest), 1% Penicillin Streptomycin (Sigma-Aldrich),
1X GlutaMAX™ (Thermo Scientific) and sodium pyru-
vate (Thermo Scientific) at 37 °C, 5% CO2 and controlled
humidity. At 80% confluency, cells were splitted twice a
week by trypsinization, centrifugation at 1000 x g (Cen-
trifuge 5810, Eppendorf), resuspension in cell culture
medium and plating at a density of 1 × 106 cells/flask
(Fisher Scientific).
To run a functional seeding assay, HEK293-FRET
CFP/YFP cells were plated into a 96 well poly-D-lysine
coated (Greiner Bio-One) at a density of 2500 cells per
well in a volume of 130 μL of cell culture medium and
kept overnight in the incubator. On the second day, the
standard curves and samples were diluted in PBS and
co-incubated with the cells. Total volume of each well
was adjusted to 150 μL with PBS. After 7 days of incuba-
tion, the cells were washed once with PBS and trypsi-
nized with 50 μL for 5 min and transferred to a
polypropylene 384 well-plate (Thermo Scientific) con-
taining 30 μL of Hank’s Balanced Salt Solution (Sigma-
Aldrich).
When transfection reagent was used during FRET analysis,
25 μL of Lipofectamine2000 is diluted in Opti-MEM with a
total volume of 1mL. 10 μL of the sample to be analyzed is
incubated in a 96 well poly-D-lysine coated (Greiner Bio-
One) plate well for 10min. After incubation 55,000 cells di-
luted in 130 μL medium are added per well. After 48 h of in-
cubation cells are collected in the same way as when not
using transfection reagent. FRET analysis was performed
with BD FACSCanto™ II (Becton Dickinson, New Jersey,
USA using the Violet laser. The Pacific Blue channel is used
to measure CFP. The AmCyan channel is used for the detec-
tion of YFP signal, but with an alternative filter set to better
separate the YFP emission from the CFP emission. In this
case, a 556LongPass and 585/42 BandPass filterset was used
instead of the 502LP and 510/50BP filterset that is normally
used in the AmCyan configuration.
Controls were done by initially gating a negative popu-
lation of cells (treated with no pro-aggregating sample).
Gating for positive cells was performed by treating cells
with a sample known to cause aggregation a FRET sig-
nal. The same gating strategy was then always applied to
each experiment and confirmed with negative and posi-
tive controls. As published in [9] Tau seeding activity is
measured in homogenates from AD brain but not in the
same homogenates from non-tauopathy brain. For
mouse brain homogenates, it was previously shown that
spinal cord homogenates from WT mice do not contain
seeding activity while in the same extracts from P301S
mice Tau seeding increases with age [13].
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Biochemical analysis using Meso scale discovery (MSD)
ELISA
Coating antibodies PT76, PT51 [13] or AT8 [26] were
diluted in PBS (1 μg/ml) and dispensed into MSD plates
(30 μL per well) (L15XA, Meso Scale Discovery), which
were incubated overnight at 4 °C. After washing with
5 × 200 μL of PBS/0.5%Tween-20, plates were blocked
with 0.1% casein in PBS and washed again with 5 ×
200 μL of PBS/0.5%Tween-20. After adding samples and
standards (both diluted in 0.1% casein in PBS), plates
were incubated overnight at 4 °C under gentle agitation.
Subsequently, the plates were washed with 5 × 200 μL of
PBS/0.5%Tween-20, and SULFO-TAG™ conjugated
detection antibody (PT76) in 0.1% casein in PBS was
added and incubated for 2 h at room temperature while
shaking at 600 rpm. After a final wash (5 × 200 μL of
PBS/0.5%Tween-20), 150 μL of 2 X buffer T (Meso Scale
Discovery) was added, and plates were read with an
MSD reader. Signal/background measurements were
calculated by dividing the signal by a measurement
where no sample was added.
Sucrose gradient
A discontinuous sucrose gradient was prepared as fol-
lowing: 1 mL of 60% (w/v) sucrose in PBS was applied to
the bottom of the tube, followed by 2 mL of 50, 40, 30
and 20% (w/v) sucrose, covered by 1 mL of 10% (w/v)
sucrose. Samples were diluted in PBS to a total volume
of 500 μL and added on top of the gradient. This was
followed by centrifugation for 16 h at 200,000 g (SW 40
Ti Swinging-Bucket Rotor) at 4 °C. Fractions of approxi-
mately 500 μL were collected and aliquoted for further
analysis.
Electron microscopy
Sonicated and non-sonicated K18 samples (4 μL) were
spotted on freshly glow-discharged carbon/formvar-
coated EM grids in a concentration of 2 μM and left to
sediment over 1 min. Excess sample was blotted off and
the grid was contrasted for 1 min with 2% uranyl acetate
(Polysciences Inc) in water. Grids were blotted and air-
dried before imaging in a Tecnai12 Biotwin TEM (FEI/
ThermoFisher) with Veleta side-mounted CCD camera
(EMSIS) at 43,000 times magnification.
Results
Biochemical analysis of K18 (P301L) fibrils with PT76, a
microtubule binding domain (MTBD)-directed Tau
antibody
Synthetic Tau-fragment-derived fibrils have been shown
to be very efficacious prion-like seeding agents in vitro
and in vivo [9, 23, 27, 28]. In these Tau seeding models,
sonication has been used to improve the seeding cap-
acity of aggregates even further. To determine the effect
of sonication on the biochemical and biophysical proper-
ties of Tau fibrils, we initiated this study by analyzing ag-
gregates composed of recombinant myc-tagged K18 Tau
fragment with a pro-aggregation P301L mutation (re-
ferred to as “K18” in this manuscript). These fibrils are
exclusively composed by identical monomeric species
thus any changes in functional properties caused by son-
ication could only be attributed to altered biophysical
properties and not to differences in protein constitution.
One important fact on these K18 Tau fragments is that
they are only composed of 4R Tau, while Tau in human
brain has multiple isoforms with 4R and 3R Tau.
From our in-house antibody collection, PT76, devel-
oped by immunization with human AD brain-derived
PHF as first described in Vandermeeren et al. [13] was
found to bind a Tau epitope encompassing residues
249–258 which is localized N-terminal from the MTBD.
Therefore, this antibody is suited to detect K18 contain-
ing samples as shown with ELISA data (Fig. S1). In
addition to an MSD assay that detects linear myc-K18
proteins, an aggregation-selective self-sandwich MSD
assay using PT76 as coating and as detection antibody
was developed. Aggregate-selectivity of this assay was
confirmed by analysis of increasing dilutions of three dif-
ferent K18 fibril preparations in comparison to dilutions
from an equivalent amount of monomeric K18 (con-
firmed by native PAGE and by different dilutions of
supernatant obtained after ultracentrifugation). The
three independent K18 fibril preparations have consist-
ent dilution curves (Fig. 1a). Almost no signal is ob-
served for dilutions of the (non-aggregated) K18
preparation before fibrillization (Fig. 1a), demonstrating
the aggregate-selectivity of the PT76/PT76 MSD assay.
This assay did also not detect substantial signals in the
supernatant after ultracentrifugation of the aggregated
K18 prep which confirmed that the majority of aggre-
gated K18 is incorporated in the pellet fraction.
Using a PT76/PT76 aggregation specific MSD on dif-
ferent dilutions of human AD enriched PHFs (ePHF)
compared to Tau fibrils derived from P301S Tau Tg
mouse brain (Fig. 1b) it was possible to observe that for
preps with similar Tau content (Fig. S2), the same dilu-
tions containing ePHF result in a much higher signal
compared to P301S derived seeds. This can be caused by
a lower PT76 epitope exposure in P301S seeds compared
with ePHF.
Sonication of K18- and human AD brain-derived fibrils
Seeding experiments using Tau fibrils often involve son-
ication to improve efficiency [23, 29]. To better under-
stand this phenomenon, a K18 fibril preparation was
divided in two aliquots, one of which was sonicated and
the other remained untreated. These samples were then
analyzed with MSD and cellular assay analysis (Fig. 2).
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When dilution series of these samples were analyzed
with a Tau aggregate-selective PT76/PT76 MSD assay,
similar signals were observed in sonicated and non-
sonicated samples (Fig. 2a) indicating that sonication did
not alter the amount of aggregated material. Conversely,
evaluation of these samples in a cellular Tau seeding
assay [9] revealed a higher signal induced by sonicated
K18 fibrils compared to equal amounts of non-sonicated
fibrils (Fig. 2a,c). This difference was more prominent
when the assay was performed in the absence of trans-
fection reagent (Fig. 2b). Together with the PT76/PT76
MSD analysis, these data demonstrate that sonication
improves the seeding potency of K18 fibrils without
changing the overall exposure of PT76 epitopes. On
one hand sonication of the fibrils could generate spe-
cies with an altered size and improved cellular uptake.
In addition, the amount of aggregates will be higher,
which can lead to more events of seeding. The ob-
served, modest, effect by sonication in % FRET posi-
tive cells in the presence of transfection reagent also
points to an improved seeding capacity independent
of uptake which is indeed observed with in vitro
seeding experiments using recombinant fibrils (Fig.
S3) and with other studies [30, 31].
A recent study [12] demonstrated efficient Tau seed-
ing in WT mouse brain by human AD brain-derived
PHFs prepared via a novel procedure. This procedure
uses extensive sonication to resuspend the pellet after
ultracentrifugation on one hand, but also additional
steps to improve the purity on the other hand. To esti-
mate the contribution of the sonication procedure to
the improved seeding potency, sonicated and non-
sonicated PHF preparations were analyzed both by vari-
ous aggregation selective MSD assays and by cellular
Tau seeding assays (Fig. 3). Self-sandwich aggregation
selective assays showed similar signals for AT8 (Fig. 3a)
and PT51 (Fig. 3b), and a slightly increased signal in
the sonicated fraction over the non-sonicated in PT76
(Fig. 3c). Like our observed improvement in seeding po-
tency of K18 fibrils, sonicated PHFs also appeared to be
more active in the cellular seeding model. Again, this
difference was more pronounced when the incubations
were performed in the absence of transfection reagent
(Fig. 3d, e).
Fig. 1 MSD analysis of recombinant and biological Tau samples. a Three different preparations of K18 aggregates were analyzed using a PT76/
PT76 aggregation selective MSD assay and compared against a representative supernatant fraction after ultracentrifugation and against an
equivalent amount of monomeric K18. b Comparison of PT76 aggregations specific MSD using two different biological sources, ePHF and P301S
spinal cord total extracts
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Sonication alters size distribution of K18 Tau fibrils
The data above demonstrate improved seeding activity
in sonicated K18 (P301L) and human AD brain-derived
Tau fibrils without changing Tau content. As this sug-
gests involvement of alterations in biophysical properties
of the fibrils, different techniques were used to demon-
strate changes in size distribution induced by the sonic-
ation procedure. First, native PAGE analysis (Fig. 4) of
sonicated and non-sonicated K18 fibrils revealed that
most non-sonicated fibrils are too large to enter the gel,
while the sonicated material migrated into the gel result-
ing in an increase of Coomassie signal (Fig. 4a). A simi-
lar separation of human AD brain-derived PHFs on
native PAGE, detected via Western blotting using Tau
antibodies binding to the N-terminus (hTau10), mid-
term (PT51), phosphorylated epitope in PRD (AT8) and
MTBD (PT76) [13] confirmed the reduction in size of
the sonicated material (Fig. 4a). Taken together, native
PAGE data provided a first indication that sonication
changes the size distribution of recombinant derived
fibrils and human-derived aggregates. This phenomenon
was characterized in more detail using sucrose gradient
ultracentrifugation to for size distribution analysis of
Tau fibrils.
Sonicated and non-sonicated K18 fibrils and non-
aggregated K18 monomers were separated by sucrose
gradient ultracentrifugation and analyzed (Fig. 5). First,
fractions were analyzed by native PAGE (Fig. 5a) and
the blots showed that signals present in higher density
fractions correspond to higher MW species. Indeed,
non-aggregated K18 was only present in the least dense
fractions while aggregated K18 is observed in high
density fractions and in the pellet, with a density above
that of 60% w/v sucrose solution. Interestingly, the sig-
nal in the pellet fraction disappeared by sonication of
the fibrils. In addition, sonication altered the size distri-
bution of K18 fibrils over the gradient with a maximum
signal in the pellet and fraction 1 of the gradient of
Fig. 2 Effect of sonication on biochemical and functional analysis of K18. a In vitro aggregated K18 fibrils (sonicated and non-sonicated), were
analyzed with a PT76/PT76 aggregation selective MSD assay. b, c Seeding capacity of K18 Tau seeds (sonicated and non-sonicated) were
investigated by adding different amounts of the preparations to K18-FRET cells, in the absence (panel b) or presence (panel c) of transfection
reagent. Induction of aggregation was evaluated and expressed as by percentage of FRET. (∗∗∗p < 0.001; ∗∗∗∗p < 0.0001, two-way
ANOVA analysis)
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Fig. 3 Effect of sonication on biochemical and functional analysis of human PHFs. a-c Different dilutions of human AD brain-derived PHFs
(sonicated and non-sonicated), were analyzed with an AT8-AT8 (a), PT51-PT51 (b) and PT76/PT76 (c) Tau aggregate selective MSD assays. (D,E)
Seeding capacity of PHF Tau seeds (sonicated and non-sonicated) were investigated by adding different amounts of the preparations to K18-FRET
cells, in the absence (panel D) or presence (panel E) of transfection reagent. Induction of aggregation was evaluated and expressed as by
percentage of FRET. (∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001; ∗∗∗∗p < 0.0001, two-way ANOVA analysis)
Fig. 4 Native page analysis of K18 and PHF fibril preparations subjected to sonication. a In vitro aggregated K18 fibrils (sonicated and non-
sonicated), non-aggregated K18 and 2N4R (WT) Tau were analyzed by native PAGE as described in materials and methods. Visualization was
performed by the presence of Coomassie brilliant blue in the native PAGE sample buffer mix. The left panel shows high MW species in both
aggregated K18 samples with a stronger signal for the sonicated sample. The right panel shows the same gel before cassette removal
demonstrating presence of large aggregates not entering the gel. b Sonicated and non-sonicated PHF aggregates were analyzed by native PAGE
as described in materials and methods. Detection was accomplished with hTau10, AT8, PT51 and PT76 -HRPO labelled antibodies
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Fig. 5 Analysis of K18 sucrose gradient ultracentrifugation fractions. Fractions obtained by sucrose gradient ultracentrifugation of aggregated, and
non-aggregated K18 protein were analyzed by Western blot under native (a) condition. Detection performed with anti-myc primary antibody and
anti-mouse HRPO-labelled secondary antibody. (Top: non-sonicated aggregated K18; middle: sonicated aggregated K18; bottom: monomeric K18).
Fraction 1 has the highest density; Fraction 19 has the lowest density. Fraction P is a resuspension of the pellet in PBS. In panel (b), an MSD
analysis of corresponding fractions using the aggregate specific PT76/PT76 assay is represented. Functional analysis of K18 sucrose gradient
fractions can be observed in panel (c). Seeding capacity in the absence of transfection reagent was evaluated by percentage of FRET positive
cells. A representative profile of at least three independent experiments is shown. K18 Tau fibrils are analyzed by electron microscopy (d-e). Non-
sonicated (d) and sonicated K18 Tau (e) samples are used for this analysis. Images are captured at 43000x magnification
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non-sonicated material to a maximal signal in fractions
4, 5 and 6 of the sonicated material.
In correspondence with these data, PT76-PT76 MSD
analysis (Fig. 5b) showed that most of the aggregate sig-
nal from the non-sonicated K18 sucrose gradient
migrated to the pellet, while the signal was spread out
through the higher density sucrose gradient fractions of
sonicated K18 fibrils, with the strongest signals in frac-
tions 4, 5 and 6. As expected, no HMW signal was
observed when analyzing sucrose gradient samples from
non-aggregated K18, probing the specificity of the assay
for aggregated structures. The seeding capacity of the
different fractions, separated by sucrose gradients, was
addressed by adding these fractions to FRET biosensor
cells. In these Tau seeding experiments, it was observed
that high-density fractions of the sonicated material
presented at least 8-fold higher seeding capacity com-
pared to the same fractions of the non-sonicated mater-
ial (Fig. 5c). (Figure 5c) and showed a good correlation
with the aggregation signal (Fig. 5b). Correlating with
the aggregation MSD assay data, only the pellet fraction
of the non-sonicated K18 fibrils showed efficient seeding
in the biosensor cells assay. The fact that seeding was
still observed in this very high-density pellet fraction
might be explained by the effect of resuspension through
up and down pipetting of this pellet during sample col-
lection. This was confirmed by native Western blotting
(Fig. 5a) showing that the resuspended pellet could enter
the gel, while also showing lower MW fibrillary species.
Nevertheless, while in the biochemical aggregation assay
this pellet fraction showed the highest signal, the seeding
potency of that sample remained lower in comparison to
the HMW fraction 5 of the sonicated gradient. Non-
aggregated K18 monomers were localized in low density
sucrose gradient fractions 17, 18 and 19 and did not
show seeding activity, confirming the specificity of the
FRET assay.
When analyzing K18 samples by electron microscopy
(Fig. 5d-e) we could observe that sonicating K18 seeds
caused an alteration in the size of the fibrils from the
non-sonicated samples (Fig. 5d) when compared to soni-
cated samples (Fig. 5e) where K18 filaments are much
shorter, confirming our observations with biochemical
assays and sucrose gradient experiments.
Size separation of human AD brain- and P301S tau
transgenic mouse brain-derived homogenates
Biochemical and functional experiments demonstrated
how sonication affects recombinant K18 fibrils. Next, we
analyzed whether this phenomenon is also occurring in
Tau seeds present in fibrils derived from postmortem
AD brain or from P301S Tau transgenic (Tg) mouse
brain [24]. In addition to this, our data already suggest
structural differences between both types of fibrils
apparent by a differential epitope exposure for anti-
bodies binding close to the MTBD: i.e. PT76 and
hTau21 [13]. Since the epitope exposure seems to
depend on the structure and composition of the aggre-
gate and since sonication has been shown to fragment
large aggregates, it was evaluated through sucrose gradi-
ent analysis (Fig. 6) if sonication impacts size distribu-
tion and epitope exposure of Tau aggregates from
human AD-brain and P301S Tg mouse aggregates.
Analysis of gradient fractions with MSD aggregation
assays using antibodies PT51 and PT76 showed that
non-sonicated human PHF fractions displayed high ag-
gregate signals in the two highest-density fractions while
the sonicated PHFs signals showed maximal intensity in
fractions 3 and 4 (Fig. 6b). A similar shift in size distri-
bution was observed in the sucrose gradient fractions
from sonicated fibrils from P301S Tau Tg mice (Fig. 6e).
This result supports the hypothesis of sonication influ-
encing size distribution of aggregates. When functional
FRET analysis of sucrose gradient fraction was per-
formed (Fig. 6c), a modest difference between sonicated
and non-sonicated Tau aggregates was observed. This
can be explained by the fact that seeding of the sucrose
gradient fractions was only observed in the presence of
transfection reagent. In the absence of transfection re-
agent, fractions became too diluted to detect Tau seed-
ing (data not shown). This indicated that postmortem
human AD brain homogenates contain lower Tau seed-
ing compared to fibrils from mutant Tau Tg mice. From
data in Fig. 3d, e it was demonstrated that the effect of
sonication on the seeding efficiency was less prominent
when transfection reagent is used.
Interestingly, sonication of P301S brain derived aggre-
gates increased exposure of the PT76 epitope in the sucrose
gradient fractions (Fig. 6e). This is consistent with data
from Vandermeeren et al., [13]. When testing the same
samples on a functional analysis it was seen that sonication
also increased the amount of aggregation on a shift on the
fractions that are responsible for seeding for a less dense
sucrose gradient fraction. Note that in this experiment the
seeding could be performed in the absence of transfection
reagent, a condition under which the effect of sonication is
more pronounced (Fig. 3, Fig. 6f).
To understand if the observation on MSD and cellular
assays are indeed due to size differences in the aggre-
gates contained in these fractions all sucrose gradient
fractions were analyzed by native PAGE and immuno-
blot detection with HRPO-labelled PT76. Native Page
blots of sucrose gradients from sonicated extracts from
human AD brain (Fig. 6a) and from P301S Tg mouse
brain (Fig. 6d) displayed a shift in Tau signals when
compared with the non-sonicated material, which is
mostly accumulated in the first fraction. This observa-
tion comes in line with both the biochemical and
Marreiro et al. BMC Molecular and Cell Biology           (2020) 21:81 Page 9 of 14
functional analysis. This confirmed that sonication af-
fects the size distribution of fibrillary Tau species in ex-
tracts from human AD brain-derived PHFs and P301S
Tau Tg mice. In addition, the increased signal in some
aggregation-selective assays (PT76/PT76) suggests sonic-
ation played a role in increasing epitope exposure.
Discussion
Spreading of Tau pathology has been postulated to be a
key driver in the observed spatiotemporal progression of
Tauopathy-mediated neurodegeneration [5]. As this
hypothesis opens the opportunity for the development
of Tau immunotherapy strategies [32], the biochemical
and biophysical properties of the Tau species responsible
for seeding in human brain are under intensive investi-
gation [8, 9, 12, 33, 34]. An important number of find-
ings demonstrated the presence of Tau seeds in
detergent insoluble preparations of Tau Tg mouse brain
[35], but also from postmortem human Tauopathy brain
[11, 12, 14]. Interestingly, the study of Guo et al. [12]
describes a novel procedure to prepare Tau aggregates,
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Fig. 6 Analysis of PHF and P301S brain extract sucrose gradient fractions. Tau fibrils derived from human AD brain (a-c) or from P301S Tau Tg
mouse spinal cord (d-f) were separated by sucrose gradient ultracentrifugation. PHF (a) and P301S (d) gradient fractions were analyzed by
Western blot under native conditions. Detection performed with PT76 primary HRPO-labelled antibody. (Top: non-sonicated; bottom: sonicated).
Fraction 1 has the highest density, fraction 19 has the lowest density. Fraction P is a resuspension of the pellet in PBS. An MSD analysis of PHF (b)
and P301S fractions is performed using the indicated aggregate selective assays are represented. Functional analysis of PHF (c) and P301S (f)
sucrose gradient fractions was performed by determining seeding capacity in the absence of transfection reagent (P301S) or in the presence of
transfection reagent (human PHF). This was evaluated by percentage of FRET-positive cells. A representative profile of at least two independent
experiments is shown
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mice. Data from our group demonstrated Tau seeding of
a sarcosyl-insoluble sample derived from postmortem
human AD brain after injection in the hippocampus of
P301L mice [13]. For both cellular and in vivo Tau seed-
ing experiments, fibrils are sonicated to improve seeding
efficiency. In this communication, we compared the size
distribution and exposure of the PT76 epitope (249–
258) of Tau fibrils from different sources (recombinant,
Tau Tg mice brain and AD brain) and evaluated how
these properties are affected by sonication.
Recently it was observed that small species of Tau
have an impact on aggregation [30, 36]. Because the
samples that we used to evaluate the effect of sonication
or are either pre-formed aggregates or sarcosyl insoluble
fractions, a limitation of this model is present. When
seed-competent monomers are used the nucleation
phase occurs, while after adding preformed fibrils, either
recombinant or brain derived, the nucleation phase is
bypassed [30, 31, 37].
After identifying and characterizing the PT76 antibody
for biochemical analysis of K18 fibrils, we compared bio-
chemical and functional properties of sonicated and
non-sonicated K18-derived fibrils, prepared according to
[23]. Although both samples induced seeding in the
FRET biosensor cells, the sonicated K18 seeds displayed
higher seeding potency and this was more pronounced
in the absence of transfection reagent, thereby suggest-
ing that sonication produces fibril fragmentation creat-
ing a higher number of available fibrils and improving
seeding efficiency. The fact that high signals are
observed when transfection reagent is used can be due
to bigger aggregates, from which the uptake is facilitated
by transfection. The fact that even under these condi-
tions, sonication shows some improvement suggests that
also the intrinsic seeding potency is increased as shown
in Fig. S3 and in other studies [30, 31]. Further
characterization of sonicated and non-sonicated K18
preparations by sucrose gradient ultracentrifugation
experiments convincingly demonstrated that sonication
induced two major alterations in the distribution of K18
aggregate species. First, the strong aggregate signal in
the pellet fraction of the non-sonicated K18 fibrils was
not observed in the sonicated K18 fibrils. Second, HMW
species in fractions displayed higher intensities in soni-
cated sample when comparing with non-sonicated. Ana-
lysis of sucrose gradient with PT76/PT76 MSD
confirmed the change in size distribution induced by the
sonication. Also, biochemical analysis matched the
observations obtained from seeding experiments with
different K18 aggregate species. Surprisingly, the pellet
fraction of non-sonicated K18 fibrils showed seeding po-
tency although this was relatively low compared to its
high aggregation signal in MSD. The observed seeding
capacity by this pellet fraction is probably due to the
resuspension of this pellet that causes limited disruption
of the original large aggregate species into lower MW
species. Low remaining monomer signals (< 2%) in
supernatant fractions after K18 aggregation and ultra-
centrifugation demonstrated that the majority of K18
signal precipitated into the pellet fraction confirming
that the aggregated conformation of K18 is important
for the seeding potency of the aggregates. The observa-
tion that sonication will lead to a break of bigger K18
aggregates into smaller forms is further supported by the
electron microscopy experiments where we could
observe clear differences after sonication of K18 Tau.
To translate our findings made with K18 fibrils to
in vivo-produced Tau aggregates from human AD
brains, we show that sonication improves the seeding
potency of these fibrils and creates smaller MW aggre-
gates, which is indicative of a similar phenomenon as
observed for K18 (P301L fibrils). Indeed, separation by
sucrose gradient ultracentrifugation confirmed that son-
ication fragments the large aggregates in smaller fibrils
with altered size distribution. Native PAGE analysis con-
firmed that the fibrils produced after sonication are
gradually smaller, correlating with the fraction-density
within the gradient. Biochemical analysis in “self-sand-
wich” MSD assays and cellular assays confirmed a shift
in the distribution of the aggregates in the sucrose gradi-
ent fractions towards lower MW species with increased
seeding potency. While PT51 detected similar signals in
the sonicated and non-sonicated gradients, AT8 and
PT76 showed some differences in epitope exposure after
sonication, suggesting that some of these epitopes are
partially shielded in the PHF structure. For PT76, previ-
ous data demonstrated that its epitope is part of the
pronase-resistant core of human PHFs and even more in
fibrils derived from P301S Tau Tg mice [13]. If sonic-
ation would also affect epitope exposure, the sonication-
induced increased PT76 signal would be expected to be
more pronounced in Tau seeds from Tg mice.
Sucrose gradient fractions from sonicated and non-
sonicated fibrils from Tau Tg mice showed a shift in size
distribution accompanied by an increase of seeding cap-
acity by the sonication procedure. Although this effect
was comparable to the sonication-driven changes on AD
brain-derived PHFs, the increased exposure of the PT76
epitope after sonication was more drastic. Since the epi-
tope of PT76 is proximate to the MTBD, in which the
hexapeptide stretches 275VQIINK280 and 306VQIVYK311
[38] have been shown to display strong propensity for β-
Sheet formation, the increased PT76 epitope exposure
after sonication could increase the exposure of the above
described pro-aggregation motifs, which may addition-
ally explain the increased seeding potency of sonicated
fibrils. Another possible reason for a more exposed epi-
tope on non-recombinant seeds after sonication is a
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reduction of other proteins sticking to the surface of
aggregates being displaced from them after sonication.
This could make that both uptake by cells and binding
of PT76 antibodies are increased. Since the fibril uptake
in the actual experiments is not quantified, imaging
studies with K18 fibrils will help to confirm the effect of
sonication on the cellular uptake of Tau fibrils.
The difference in PT76 signal between P301S and
human derived PHF sucrose gradient fractions also sug-
gests that there is an intrinsic difference in these aggre-
gates’ structure and consequent exposure to PT76.
According with results from Fitzpatrick et al., [18] PT76
epitope is in a region outside the core of the aggregate.
This would mean that even in high molecular weight
NFT’s this epitope would be to some extent exposed.
This also correlates with our previous observations using
pronase [13] where PT76 epitope was more conserved in
P301S aggregates after proteolysis than PHF. Finally, ob-
servations using trypsin made by Watanabe et al., [39]
showed that PT76 is outside the trypsin resistant core of
the aggregate, which would mean that this epitope is ex-
posed in Tau aggregates obtained from AD patients
postmortem material.
A study with sucrose gradient separation of P301S Tg
mouse seeds [35] also demonstrated that small fibrils,
but not monomeric or small oligomeric Tau species, are
the most seeding-competent species in vitro and in vivo.
In that study, seeding-competent species were present in
the 40% sucrose gradient, while the fibrils present in the
50% sucrose fraction where no longer seeding compe-
tent. This suggests a limit to the size of the aggregates
that allows cellular uptake. Also, Wu and colleagues [4]
demonstrated that in cells, recombinant Tau firstly mis-
folds into low MW aggregates that then further assemble
into fibrils. While the low MW aggregates can be taken
up by neuronal cells, the long fibrils extracted from hu-
man brains were not taken up. The authors hypothe-
sized that internalization of Tau aggregates in cultured
neurons depends on the conformation and size of the
aggregates, which is in accordance with the findings de-
scribed here. If so, this study explains the requirement of
the sonication of Tau seeds in in vitro and in vivo stud-
ies that are currently in use to investigate pre-clinical
evaluation of Tau antibodies.
Small oligomeric species with potent seeding activity,
as suggested by two previous studies [34, 40] were not
observed, which is in accordance with previous data [13]
and work from Jackson and colleagues [35] showing that
short fibrils are the seeding-competent Tau species that
are present in brain homogenates from P301S Tau Tg
mice. Collectively, the experiments comparing sonicated
and non-sonicated K18 aggregate species confirm seed-
ing capacity of larger MW aggregates, but not of oligo-
mers, which were not observed in the analyzed samples.
Moreover, separation of human AD brain- and P301S
Tau Tg mice brain-derived fibrils by means of a sucrose
gradient also reveals that the major seeding competent
fractions of these samples are present in high MW frac-
tions as confirmed by native PAGE blots. Here, the son-
ication generates a shift in size distribution combined
with an increased exposure of epitopes close to the
MTBD. Previous work suggested that exposure of these
epitopes can be determined by the structural alterations
between recombinant fibrils and fibrils derived from
tauopathy brain [17]. In addition, conformational tem-
plating assumes [21] that also between different tauopa-
thies, fibril structure and epitope exposure can vary [18].
The knowledge of which size of aggregates is responsible
for seeding and which antibodies better recognize these
forms of Tau can have an impact in how antibodies are
selected for therapy, not only for AD but also for other
tauopathies, such as Progressive supranuclear palsy, cor-
ticobasal degeneration or frontotemporal dementia.
These analyses could be applied to these different Tauo-
pathies in order to understand in which fractions are the
more toxic species of Tau and which are more recog-
nized by certain antibodies. By understating the differ-
ences and similarities between these disorders one could
find better tools to study and potentially treat them.
The results in this work also suggest that smaller spe-
cies of Tau fibrils are more involved with the progres-
sion of the disease. This would mean that a potential
therapy would ideally target Tau fragments in an early
stage of the progression of the disease, where the big
neurofibrillary tangles are not yet formed. This work
provides insight in the size distribution and epitope ex-
posure of the different Tau fibrillary species derived
from different sources and how these properties correl-
ate to their seeding potency while also giving us better
tools to study Tau aggregation. In particular, the effect
of sonication on recombinant and human AD brain-
derived extracts, which are being used in different cellu-
lar and in vivo seeding models, is demonstrated and
explained. This knowledge can provide a better under-
standing of the properties of the true Tau seeding com-
ponents during disease progression and how to target
these by immunotherapy.
Conclusions
Taken together, this work suggest that sonication affects
biochemical, biophysical and functional properties of
Tau aggregates from different sources such as in vitro
aggregated K18 and postmortem preparations from hu-
man AD brain and P301S Tau Tg mouse brain. Data
provided in this manuscript supported two phenomena:
1. Sonication breaks large aggregates into smaller sized
fibrils. While the effect of size distribution was very
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prominent for K18 fibrils, this was also observed for
the aggregates derived from human and Tau Tg
mouse brains.
2. Sonication increases intrinsic seeding potency
in vitro which also contributes to the effect of
sonication on the seeding efficiency of postmortem
brain homogenates observed after transfection
(which bypasses the limitation of cellular uptake).
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